Physostigmine as a Treatment for Gamma-Hydroxybutyrate Toxicity: A Review

REFERENCES

• Schwartz R.H., Milteer R., LeBeau M.A. Drug-Facilitated Sexual Assault (“Date Rape”). South. Med. J. 2000; 93: 558–561
   PubMed Web of Science ®Google Scholar
• , Drug Abuse Warning Network. The DAWN Report: Club Drugs—December 2000. (accessed May 10, 2002).
   Google Scholar
• Chin R.L., Sporer K.A., Cullison B., Dyer J.E., Wu T.D. Clinical Course of γ-Hydroxybutyrate Overdose. Ann. Emerg. Med. 1998; 31(6)716–722
   PubMed Web of Science ®Google Scholar
• Li J., Stokes S.A., Woeckener A. A Tale of Novel Intoxication: A Review of the Effects of γ-Hydroxybutyric Acid with Recommendations for Management. Ann. Emerg. Med. 1998; 31(6)729–736
   PubMed Web of Science ®Google Scholar
• Okun M.S., Boothby L.A., Bartfield R.B., Doering P.L. GHB: An Important Pharmacologic and Clinical Update. J. Pharm. Sci. 2001; 4(6)167–175
   Google Scholar
• Vayer P. Minireview: Gamma-Hydroxybutyrate, a Possible Neurotransmitter. Life Sci. 1987; 41: 1547–1557
   PubMed Web of Science ®Google Scholar
• Cash C.D. Gammahydroxybutyrate: An Overview of the Pros and Cons for it Being a Neurotransmitter and/or a Useful Therapeutic Agent. Neurosci. Biobehav. Rev. 1994; 18(2)291–304
   PubMed Web of Science ®Google Scholar
• Tunnicliff G. Sites of Action of Gamma-Hydroxybutyrate (GHB)—A Neuroactive Drug with Abuse Potential. J. Toxicol. Clin. Toxicol. 1997; 35(6)581–590
   PubMed Web of Science ®Google Scholar
• Snead O.C. Evidence for a G Protein-Coupled Gamma-Hydroxybutyric Acid Receptor. J. Neurochem. 2000; 75(5)1986–1996
   PubMed Web of Science ®Google Scholar
• Howland M.A. Antidotes in Depth: Physostigmine. Goldfrank's Toxicologic Emergencies, L.R. Goldfrank, N.E. Flomenbaum, N.A. Lewin, R.S. Weisman, M.A. Howland, R.S. Hoffman. 6th Ed.;, Appleton & Lange, Stamford, CT 1998; 614–617
   Google Scholar
• Havasi G., Havasi I., Gintautas J., Kraynack B.J. Is Physostigmine a Pure Analeptic Agent? A Clinical Evaluation. Proc. West. Pharmacol. Soc. 1982; 25: 35–37
   PubMedGoogle Scholar
• Nattel S., Bayne L., Ruedy J. Physostigmine in Coma Due to Drug Overdose. Clin. Pharmacol. Ther. 1979; 25(1)97–102
   Google Scholar
• Nilsson E. Physostigmine Treatment in Various Drug-Induced Intoxications. Ann. Clin. Res. 1982; 14: 165–172
   PubMedGoogle Scholar
• Rupreht J., Dworacek B. Physostimine Versus Naloxone in Heroin-Overdose. J. Toxicol. Clin. Toxicol. 1983–84; 21(3)387–397
   PubMed Web of Science ®Google Scholar
• Livingston A., Waterman A. The Effects of Cholinergic and Anticholinergic Drug on Ketamine Anaesthesia in Rats [Proceedings]. J. Physiol. 1978; 277: 56P
   Google Scholar
• Foote G., Livingston A. A Comparison of the Effects of Physostigmine and Atropine on Ketamine, Althesin and Pentobarbitone in Rats [Proceedings]. J. Physiol. 1978; 284: 132P–133P
   Google Scholar
• Di Liberti J., O'Brien M.L., Turner T. The Use of Physostigmine as an Antidote in Accidental Diazepam Intoxication. J. Pediatr. 1975; 86: 106–107
   PubMed Web of Science ®Google Scholar
• Yates S.W., Viera A.S. Physostigmine in the Treatment of Gamma-Hydroxybutyric Acid Overdose. Mayo Clin. Proc. 2000; 75: 401–402
   PubMed Web of Science ®Google Scholar
• Caldicott D.G., Kuhn M. Gamma-Hydroxybutyrate Overdose and Physostigmine: Teaching New Tricks to an Old Drug?. Ann. Emerg. Med. 2001; 37: 99–102
   PubMed Web of Science ®Google Scholar
• Henderson R.S., Holmes C.M. Reversal of the Anaesthetic Action of Sodium Gamma-Hydroxybutyrate. Anesthesiol. Intensive Care 1976; 4: 351–354
   PubMedGoogle Scholar
• Holmes C.M., Henderson R.S. The Elimination of Pollution by a Non-inhalational Technique. Anaesthesiol. Intensive Care 1978; 6: 120–124
   PubMed Web of Science ®Google Scholar
• Mullins M.E., Dribben W. The Use of Physostigmine in the Management of Gamma-Hydroxybutyrate Overdose. Ann. Emerg. Med. 2001; 38: 347–348
   PubMed Web of Science ®Google Scholar
• Boyer E.W., Quang L., Woolf A., Shannon M. Use of Physostigmine in the Management of Gamma-Hydroxybutyrate Overdose. Ann. Emerg. Med. 2001; 38(3)346–347
   PubMed Web of Science ®Google Scholar
• Holmes C.M. “Fantasy”—Drug of Abuse. N. Z. Med. J. 2000; 114(1107)129
   Google Scholar
• Dean W. Physostigmine Treatment of γ-Hydroxybutyric Acid Overdose: Appropriate or Inappropriate Use of a Reversal Agent? (Letter). Mayo Clin. Proc. 2000; 75: 872
   PubMed Web of Science ®Google Scholar
• Mullins M.E., Dribben W. Physostigmine Treatment of γ-Hydroxybutyric Acid Overdose: Appropriate or Inappropriate Use of a Reversal Agent? (Letter). Mayo Clin. Proc. 2000; 75: 871–872
   PubMed Web of Science ®Google Scholar
• Nelson L.S., Howland M.A., Hoffman R.S. Central Nervous System Depression After Ingestion of RenewTrient (Letter). N. Engl. J. Med. 1999; 343: 570
   Google Scholar
• Viera A.J., Yates S.W. Toxic Ingestion of Gamma-Hydroxybutyric Acid. South. Med. J. 1999; 92(4)404–405
   PubMed Web of Science ®Google Scholar
• Ward D. Physostigmine Treatment of γ-Hydroxybutyric Acid Overdose: Appropriate or Inappropriate Use of a Reversal Agent? (Letter). Mayo Clin. Proc. 2000; 75: 870–871
   PubMedGoogle Scholar
• Olson K.R., Dyer J.E., Haller C. Central Nervous System Depression After Ingestion of RenewTrient (Letter). N. Engl. J. Med. 1999; 343: 570
   Google Scholar
• Gorton C. Butyrolactone-Induced Central Nervous System Depression After Ingestion of RenewTrient, a “Dietary Supplement” (Letter). N. Engl. J. Med. 1989; 339: 848
   Google Scholar
• Yates S. Physostigmine Treatment of γ-Hydroxybutyric Acid Overdose: Appropriate or Inappropriate Use of a Reversal Agent? (Letter). Mayo Clin. Proc. 2000; 75: 872–873
   PubMed Web of Science ®Google Scholar
• Kuhn M., Caldicott K. Use of Physostigmine in the Management of Gamma-Hydroxybutyrate Overdose. Ann. Emerg. Med. 2001; 38(3)347–348
   PubMed Web of Science ®Google Scholar
• Kleinschmidt S., Schellhase C., Mertzlufft F. Continuous Sedation During Spinal Anesthesia: Gamma-Hydroxybutyrate vs. Propofol. Eur. J. Anesthesiol. 1999; 16: 23–30
   PubMed Web of Science ®Google Scholar
• Larson G.F., Hulbert B.J., Wingard D.W. Physostigmine Reversal of Diazepam-Induced Depression. Anesth. Analg. 1977; 56: 348–351
   PubMed Web of Science ®Google Scholar
• Bidwai A.V., Stanley T.H., Gogers C., Riet E.K. Reversal of Diazepam-Induced Postanesthetic Somnolence with Physostigmine. Anesthesiology 1979; 51: 256–259
   PubMed Web of Science ®Google Scholar
• Nagy J.L., Decsi L. Physostigmine, a Highly Potent Antidote for Acute Experimental Diazepam Intoxication. Neuropharmacology 1978; 17: 469–475
   PubMed Web of Science ®Google Scholar
• Avant G.R., Speeg K.V., Freemon F.R., Schenker S., Bermak M.L. Physostigmine Reversal of Diazepam-Induced Hypnosis: A Study in Human Volunteers. Ann. Intern. Med. 1979; 91: 53–55
   PubMed Web of Science ®Google Scholar
• Wax P.M. Analeptic Use in Clinical Toxicology: A Historical Appraisal. J. Toxicol. Clin. Toxicol. 1997; 35(2)203–209
   PubMed Web of Science ®Google Scholar
• Clemmesen C., Nilsson E. Therapeutic Trends in the Treatment of Barbiturate Poisoning (The Scandinavian Method). Clin. Pharmacol. Ther. 1961; 2(2)220–229
   PubMed Web of Science ®Google Scholar
• Sethy V.H., Roth R.H., Walters J.R., Marini J., Van Woert M.H. Effect of Anesthetic Doses of γ-Hydroxybutyrate on the Acetylcholine Content of Rat Brain. Naunyn-Schmiedebergs Arch. Pharmacol. 1976; 295: 9–14
   PubMed Web of Science ®Google Scholar
• Ladinsky H., Consolo S., Zatta A., Vezzani A. Mode of Action of Gamma-Butyrolactone on the Central Cholinergic System. Naunyn-Schmiedebergs Arch. Pharmacol. 1983; 322: 42–48
   PubMed Web of Science ®Google Scholar
• Giaraman N.J., Schmidt K.F. Some Neurochemical Aspects of the Depressant Action of γ-Butyrolactone on the Central Nervous System. Br. J. Pharmacol. 1963; 20: 563–568
   Web of Science ®Google Scholar
• Muller-Schwefe G., Penn R.D. Physostigmine in the Treatment of Intrathecal Baclofen Overdose. J. Neurosurg. 1989; 71: 273–275
   PubMed Web of Science ®Google Scholar
• Saltuari L., Baumgartner H., Kofler M., Schmutzhard E., Russegger L., Aichner F., Gerstenbrand F. Failure of Physostigmine in the Treatment of Acute Severe Intrathecal Baclofen Intoxication. N. Engl. J. Med. 1990; 322: 1533–1534
   PubMed Web of Science ®Google Scholar
• Delhaas E.M., Brouwers J.R. Intrathecal Baclofen Overdose: Report of 7 Events in 5 Patients and Review of the Literature. Int. J. Clin. Pharmacol. Ther. Toxicol. 1991; 29: 274–280
   PubMedGoogle Scholar
• Rushman S., McLaren I. Management of Intrathecal Baclofen Overdose. Intensive Care Med. 1999; 25(2)239
   PubMed Web of Science ®Google Scholar
• Kirk M.A. Anticholinergics and Antihistamines. Clinical Management of Poisoning and Drug Overdose, L.M. Haddad, M.W. Shannon, J.F. Winchester. 3rd Ed.;, W.B. Saunders Co., Philadelphia 1998; 641–649
   Google Scholar